HBV Mutation Detail Information

> L180M Search Result

Mutation Information

Mutation Site	L180M
Mutation Type	Amino acid level
Gene/Protein/Region Type	RT
Relevant Drug	lamivudine (LAM)
Country	North USA; Europe; and New Zealand

Literature Information

PubMed PMID	24368224
Disease	Chronic hepatitis B
Published Year	2014
Journal	Gastroenterology
Title	Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B.
Author	Fung S,Kwan P,Fabri M,Horban A,Pelemis M,Hann HW,Gurel S,Caruntu FA,Flaherty JF,Massetto B,Dinh P,Corsa A,Subramanian GM,McHutchison JG,Husa P,Gane E
Evidence	Patients were hepatitis B e antigen (HBeAg)-positive or HBeAg-negative, with levels of HBV DNA >/=3 log10 IU/mL and lamivudine resistance mutations (HBV polymerase or reverse transcriptase amino acid substitutions rtM204I/V +/- rtL180M by INNO-LiPA Multi-DR v3; Innogenetics, Inc, Alpharetta, GA).

Contents
Description

Mutation Information Note

Gene/Protein/Region Type: Virus Gene (e.g. LMP-1) or Virus Protein (e.g. Rep 68) or Virus Region (e.g. S, X)

Literature Information Note

Evidence: sentence contains this mutation information in the citation